首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

2103124

全球偏頭痛患者人數分析與預測：2026-2035年

Global Migraine Patient Population Analysis and Forecast, 2026 - 2035

出版日期: 2026年07月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球偏頭痛患者人數持續上升，反映出偏頭痛這家全球最常見的神經系統疾病之一，其疾病負擔日益惡化。患者分析能夠全面揭示疾病的盛行率、發病率、確診和治療患者人數、人口分佈、疾病嚴重程度、年齡和性別趨勢、區域流行病學背景以及未來患者成長預測。人們對偏頭痛作為一種慢性神經系統疾病的認知不斷提高，診斷技術的進步以及頭痛專家服務的普及，都有助於提高診斷率並改善疾病的長期管理。

偏頭痛的特徵是反覆出現中度至重度頭痛，常伴隨噁心、嘔吐、畏光和畏聲，部分患者還會出現徵兆。全球疾病負擔（GBD）分析估計，全球約有11.6億至12億人患有偏頭痛，它是導致殘疾的主要原因之一，尤其是在15至49歲人群中。雖然偏頭痛可發生於任何年齡，但荷爾蒙和生物因素使得女性的發生率顯著高於男性。

全球偏頭痛患者族群受多種因素影響，包括遺傳傾向、環境誘因、壓力、睡眠障礙、肥胖、荷爾蒙變化、合併精神健康問題以及生活方式。人口成長、都市化、職場壓力增加以及人們對神經系統疾病認知的提高，導致偏頭痛確診病例數量持續成長。儘管仍有相當一部分患者未被診斷或治療不足，但神經科醫生、頭痛專家、遠端醫療服務和數位醫療平台的普及正在提高患者的認知度和治療覆蓋率。

在全球範圍內，透過增加對神經學研究、醫療基礎設施、精準醫療、穿戴式監測技術和數位化頭痛管理解決方案的投資，偏頭痛的治療水準正在不斷提高。隨著醫療服務提供者日益重視預防性護理、個人化醫療和早期療育，預計在預測期內，偏頭痛的診斷和治療患者人數將穩步成長。

市場促進因素

全球疾病負擔日益加重

偏頭痛盛行率不斷上升，持續推動人們對改善診斷、預防保健和長期疾病管理的需求。

公眾意識的提高促進了早期諮商和治療的發展。

診斷技術的進步和意識的提高

在醫療保健專業人員中，越來越多的人開始意識到偏頭痛不是短暫的頭痛，而是慢性神經系統疾病。

由於公眾意識宣傳活動和臨床指南的改進，診斷率持續上升。

擴大神經科專科服務

頭痛專科診所、神經科中心和遠端醫療平台的增加，使得患者更容易獲得專科護理。

早期療育有助於改善疾病控制，提高生活品質。

數位健康科技的進步

數位頭痛日記、穿戴式監測設備、行動醫療應用程式和人工智慧驅動的臨床決策支援正在增強疾病進展追蹤和患者監測。

這些技術能夠實現更準確的診斷，並為每位患者制定個人化的治療方案。

擴大醫療保健投資

醫療保健成本不斷上漲，以及對神經系統疾病治療的持續投入，正在加強已開發市場和新興市場的患者篩檢、診斷和長期管理。

區域洞察

北美地區確診偏頭痛患者數量位居世界前列，這得益於其先進的醫療保健基礎設施、完善的神經系統疾病診療體系、較高的疾病認知度以及創新療法的廣泛應用。預防性療法的引入和數位醫療的整合進一步提升了病患管理水準。

歐洲有大量偏頭痛患者，這得益於完善的醫療保健體系、專業的頭痛中心以及對神經學研究的持續投入。德國、英國、法國、義大利和西班牙在各自社區的偏頭痛治療和診斷方面持續做出重大貢獻。

在亞太地區，受醫療保健基礎設施擴張、對神經系統疾病的認知提高、醫療保健支出增加以及獲得專業護理的機會改善等因素的推動，預計中國、日本、印度、韓國和澳洲在預測期內將經歷偏頭痛診斷病例成長最快的時期。

在拉丁美洲、中東和非洲，隨著醫療保健系統的現代化、神經科服務的擴展、公眾意識的提高以及獲得先進治療的機會改善，偏頭痛的診斷狀況正在逐步改善。

本報告對全球偏頭痛市場進行了調查，重點關注患者群體分析。報告內容涵蓋偏頭痛概述及其臨床背景、按患者類型分類的患者數量趨勢和預測、按性別和年齡層等不同類別進行的詳細分析、區域和主要國家趨勢、競爭格局、主要公司概況以及未來展望。

全球市場預測
- 預測現有患者數量
- 預測新增病例數
- 預計確診患者人數
- 預測需要治療的患者人數
預測因素
- 人口成長的影響
- 老化的影響
- 診斷能力提升的影響
- 改善醫療保健服務的影響
預測約束
- 漏診的挑戰
- 醫療保健基礎設施方面的差異
- 治療獲取限制

第9章：醫療保健服務取得與病人就醫歷程分析

患者就診過程分析
- 症狀表現
- 參觀醫療機構
- 診斷
- 開始治療
醫療保健服務獲取評估
- 獲得基層醫療
- 神經科醫生數量是否足夠
- 遠端醫療的應用
醫療服務取得上的差異
- 收入不平等
- 區域差異
- 保險覆蓋範圍的影響

第10章區域分析

北美洲
歐洲
亞太地區
拉丁美洲

第11章主要國家分析

加拿大
德國
中國
日本
印度

第12章：對公共衛生和醫療保健系統的影響

醫療資源的利用
- 門診就診
- 急診門診使用情形
- 住院趨勢
經濟負擔分析
- 直接成本
- 間接費用
- 生產力損失
公共衛生舉措
- 意識提升計劃
- 與篩檢相關的舉措
- 無障礙改善計劃

第13章：未來展望與策略洞察

流行病學視角
醫療保健系統展望
戰略洞察

第14章：調查方法與資料框架

簡介目錄

Product Code: KSI-008926

The global migraine patient population continues to expand, reflecting the increasing burden of one of the world's most prevalent neurological disorders. Patient population analysis provides comprehensive insights into disease prevalence, incidence, diagnosed and treated patient populations, demographic distribution, disease severity, age and gender trends, regional epidemiology, and future patient growth projections. Rising awareness of migraine as a chronic neurological condition, improvements in diagnostic practices, and expanding access to specialized headache care are contributing to higher diagnosis rates and improved long-term disease management.

Migraine is characterized by recurrent episodes of moderate-to-severe headache often accompanied by nausea, vomiting, photophobia, phonophobia, and, in some patients, aura. Recent Global Burden of Disease analyses estimate that migraine affects approximately 1.16-1.20 billion people globally, making it one of the leading causes of disability, particularly among individuals between 15 and 49 years of age. Although migraine affects individuals across all age groups, women are disproportionately affected because of hormonal and biological factors.

The global patient population is influenced by genetic susceptibility, environmental triggers, stress, sleep disorders, obesity, hormonal changes, psychiatric comorbidities, and lifestyle factors. Population growth, urbanization, increasing workplace stress, and greater awareness of neurological disorders are contributing to the steady rise in diagnosed migraine cases. While a substantial proportion of patients continue to remain undiagnosed or inadequately treated, expanding access to neurologists, headache specialists, telemedicine services, and digital healthcare platforms is improving patient identification and treatment coverage.

Growing investments in neurological research, healthcare infrastructure, precision medicine, wearable monitoring technologies, and digital headache management solutions continue strengthening migraine care worldwide. As healthcare providers increasingly emphasize preventive treatment, personalized medicine, and early intervention, the diagnosed and treated patient population is expected to increase steadily throughout the forecast period.

Market Drivers

Increasing Global Disease Burden

The rising prevalence of migraine continues to create substantial demand for improved diagnosis, preventive care, and long-term disease management.

Growing public awareness is encouraging earlier consultation and treatment initiation.

Improved Diagnosis and Awareness

Healthcare providers are increasingly recognizing migraine as a chronic neurological disorder rather than an episodic headache condition.

Public education campaigns and improved clinical guidelines continue supporting higher diagnosis rates.

Expansion of Specialized Neurology Services

Growing numbers of headache clinics, neurology centers, and telemedicine platforms are improving patient access to specialist care.

Early intervention is contributing to better disease management and improved quality of life.

Advances in Digital Health Technologies

Digital headache diaries, wearable monitoring devices, mobile health applications, and artificial intelligence-assisted clinical decision support are enhancing disease tracking and patient monitoring.

These technologies support more accurate diagnosis and personalized treatment planning.

Increasing Healthcare Investment

Rising healthcare expenditure and continued investment in neurological care are strengthening patient screening, diagnosis, and long-term management across developed and emerging markets.

Market Restraints

Underdiagnosis and Undertreatment

A significant proportion of migraine sufferers remain undiagnosed because symptoms are often underestimated or self-managed without professional medical evaluation.

Limited awareness continues to delay diagnosis and treatment.

Limited Access to Specialists

Many developing countries continue experiencing shortages of neurologists and dedicated headache clinics.

Healthcare disparities limit timely diagnosis and comprehensive patient management.

Variability in Clinical Presentation

Migraine presents with diverse symptoms, attack frequencies, and severity levels, making diagnosis and patient classification challenging in some clinical settings.

Patient Population Insights

By Disease Type

The migraine patient population includes individuals with episodic migraine, chronic migraine, migraine with aura, migraine without aura, vestibular migraine, and medication-overuse headache associated with chronic migraine.

Episodic migraine represents the largest patient segment, while chronic migraine accounts for a disproportionate share of healthcare utilization and disability.

By Age Group

Migraine affects individuals of all ages but is most commonly diagnosed among adolescents and adults between 15 and 49 years, representing one of the leading causes of disability during peak working years.

By Gender

Women experience migraine significantly more frequently than men because of hormonal fluctuations and reproductive factors.

The female patient population consistently represents the largest share across global epidemiological studies.

By Treatment Status

The patient population includes diagnosed patients receiving acute therapies, preventive medications, biologics, and neuromodulation treatments, as well as a substantial number of undiagnosed or untreated individuals who represent significant unmet clinical need.

Regional Insights

North America represents one of the largest diagnosed migraine patient populations owing to advanced healthcare infrastructure, widespread neurological care, high disease awareness, and broad access to innovative therapies. Preventive treatment adoption and digital health integration continue supporting improved patient management.

Europe maintains a substantial migraine patient population supported by comprehensive healthcare systems, specialized headache centers, and increasing investment in neurological research. Germany, the United Kingdom, France, Italy, and Spain continue contributing significantly to regional patient care and diagnosis.

Asia Pacific is expected to witness the fastest growth in diagnosed migraine patients during the forecast period due to expanding healthcare infrastructure, increasing awareness of neurological disorders, rising healthcare expenditure, and improved access to specialist care across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving migraine diagnosis through healthcare modernization, expanding neurology services, increasing public awareness, and improved availability of advanced therapies.

Competitive and Strategic Outlook

The expanding migraine patient population continues creating substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, diagnostic technology developers, and digital health organizations. Industry participants are increasingly investing in early diagnosis initiatives, wearable monitoring technologies, artificial intelligence-assisted diagnostics, remote patient monitoring, and precision neurology to improve patient identification and long-term management.

Strategic collaborations among healthcare providers, pharmaceutical companies, research institutions, and digital health developers continue strengthening epidemiological surveillance and supporting improved patient outcomes. Future healthcare strategies are expected to emphasize preventive care, personalized treatment, digital patient engagement, and broader access to specialized headache services.

Conclusion

The global migraine patient population is expected to continue increasing throughout the forecast period as population growth, aging, urbanization, lifestyle changes, and greater awareness of neurological disorders contribute to higher diagnosis rates. With an estimated 1.2 billion people affected worldwide, migraine remains one of the leading causes of disability and a major public health challenge. Continued advances in diagnostic technologies, digital healthcare, preventive therapies, and specialized neurological care are expected to improve patient identification and long-term disease management. Despite challenges related to underdiagnosis, unequal healthcare access, and variability in clinical presentation, ongoing investment in neurological care and research is expected to strengthen patient outcomes while supporting future market growth.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of global migraine prevalence, incidence, diagnosed patient population, demographic trends, and disease burden.
Patient Population Assessment: Analyze patient distribution by age, gender, disease subtype, treatment status, and geographic region.
Market Drivers and Future Trends: Understand epidemiological developments, diagnosis trends, and future patient population growth.
Actionable Recommendations: Support healthcare planning, commercial forecasting, clinical development, and market expansion strategies.
Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, public health agencies, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiology assessment, commercial opportunity analysis, clinical trial planning, healthcare resource allocation, product launch strategy, investment analysis, market entry planning, and competitive intelligence.

Report Coverage

Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
Patient population analysis by prevalence, incidence, diagnosed cases, disease subtype, age group, gender, treatment status, and region
Assessment of disease burden, diagnosis trends, healthcare access, unmet clinical needs, and future patient growth projections
Analysis of patient management trends, healthcare infrastructure, and evolving diagnostic technologies
Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

1. Executive Summary

1.1 Study Overview
- 1.1.1 Scope and Objectives
- 1.1.2 Patient Population Assessment Framework
- 1.1.3 Key Findings
1.2 Epidemiology Highlights
- 1.2.1 Prevalent Population Overview
- 1.2.2 Incident Population Overview
- 1.2.3 Diagnosed Population Overview
- 1.2.4 Treated Population Overview
1.3 Forecast Highlights
- 1.3.1 Patient Population Forecast (2025-2035)
- 1.3.2 Diagnosis Rate Trends
- 1.3.3 Treatment Uptake Trends

2. Disease Overview and Clinical Background

2.1 Migraine Disease Overview
- 2.1.1 Disease Definition
- 2.1.2 Classification Systems
- 2.1.3 Disease Pathophysiology
2.2 Disease Types
- 2.2.1 Episodic Migraine
- 2.2.2 Chronic Migraine
- 2.2.3 Migraine With Aura
- 2.2.4 Migraine Without Aura
2.3 Disease Burden
- 2.3.1 Disability Burden
- 2.3.2 Quality of Life Impact
- 2.3.3 Economic Burden
- 2.3.4 Healthcare Resource Utilization

3. Epidemiology Methodology

3.1 Data Collection Framework
- 3.1.1 Population-Based Studies
- 3.1.2 Registry Data Sources
- 3.1.3 Government Health Databases
- 3.1.4 Published Literature Review
3.2 Forecasting Methodology
- 3.2.1 Base Year Estimation
- 3.2.2 Forecast Modeling Assumptions
- 3.2.3 Sensitivity Analysis
3.3 Epidemiological Definitions
- 3.3.1 Total Population
- 3.3.2 Prevalent Cases
- 3.3.3 Incident Cases
- 3.3.4 Diagnosed Cases
- 3.3.5 Treated Cases

4. Global Patient Population Analysis

4.1 Total Migraine Population
- 4.1.1 Historical Trends
- 4.1.2 Current Patient Population
- 4.1.3 Forecast Trends
4.2 Prevalence Analysis
- 4.2.1 Global Prevalence
- 4.2.2 Age-Specific Prevalence
- 4.2.3 Gender-Specific Prevalence
- 4.2.4 Regional Variability
4.3 Incidence Analysis
- 4.3.1 Global Incidence
- 4.3.2 Age-Specific Incidence
- 4.3.3 Gender-Specific Incidence
- 4.3.4 Longitudinal Trends

5. Diagnosed Patient Population Analysis

5.1 Diagnosed Population Overview
- 5.1.1 Diagnosed Cases by Region
- 5.1.2 Diagnosis Rate Trends
- 5.1.3 Diagnosis Gap Assessment
5.2 Diagnostic Pathway Analysis
- 5.2.1 Time to Diagnosis
- 5.2.2 Specialist Consultation Patterns
- 5.2.3 Misdiagnosis Rates
5.3 Undiagnosed Population Assessment
- 5.3.1 Estimated Undiagnosed Population
- 5.3.2 Key Diagnostic Barriers
- 5.3.3 Awareness Impact Analysis

6. Treated Patient Population Analysis

6.1 Treatment-Seeking Population
- 6.1.1 Healthcare Utilization Patterns
- 6.1.2 Treatment Adoption Trends
- 6.1.3 Treatment Persistence
6.2 Treated Population Segmentation
- 6.2.1 Acute Treatment Population
- 6.2.2 Preventive Treatment Population
- 6.2.3 Combination Therapy Population
6.3 Treatment Access Assessment
- 6.3.1 Healthcare Access Barriers
- 6.3.2 Reimbursement Influence
- 6.3.3 Socioeconomic Impact

7. Demographic Analysis

7.1 Age-Based Analysis
- 7.1.1 Pediatric Population
- 7.1.2 Adolescent Population
- 7.1.3 Adult Population
- 7.1.4 Elderly Population
7.2 Gender-Based Analysis
- 7.2.1 Female Patient Population
- 7.2.2 Male Patient Population
- 7.2.3 Gender-Specific Disease Burden
7.3 Urban vs Rural Analysis
- 7.3.1 Urban Patient Population
- 7.3.2 Rural Patient Population
- 7.3.3 Healthcare Access Differences

8. Patient Population Forecast Analysis (2025-2035)

8.1 Global Forecast
- 8.1.1 Prevalent Population Forecast
- 8.1.2 Incident Population Forecast
- 8.1.3 Diagnosed Population Forecast
- 8.1.4 Treated Population Forecast
8.2 Forecast Drivers
- 8.2.1 Population Growth Impact
- 8.2.2 Aging Population Impact
- 8.2.3 Diagnostic Improvement Impact
- 8.2.4 Healthcare Access Impact
8.3 Forecast Constraints
- 8.3.1 Underdiagnosis Challenges
- 8.3.2 Healthcare Infrastructure Gaps
- 8.3.3 Treatment Accessibility Limitations

9. Healthcare Access and Patient Journey Analysis

9.1 Patient Journey Mapping
- 9.1.1 Symptom Onset
- 9.1.2 Healthcare Engagement
- 9.1.3 Diagnosis
- 9.1.4 Treatment Initiation
9.2 Healthcare Access Assessment
- 9.2.1 Primary Care Access
- 9.2.2 Neurologist Availability
- 9.2.3 Telemedicine Utilization
9.3 Treatment Access Inequalities
- 9.3.1 Income-Based Differences
- 9.3.2 Geographic Disparities
- 9.3.3 Insurance Coverage Impact

10. Geographic Analysis

10.1 North America
- 10.1.1 Patient Population
- 10.1.2 Diagnosis Trends
- 10.1.3 Treatment Access
10.2 Europe
- 10.2.1 Patient Population
- 10.2.2 Diagnosis Trends
- 10.2.3 Treatment Access
10.3 Asia-Pacific
- 10.3.1 Patient Population
- 10.3.2 Diagnosis Trends
- 10.3.3 Treatment Access
10.4 Latin America
- 10.4.1 Patient Population
- 10.4.2 Diagnosis Trends
- 10.4.3 Treatment Access
10.5 Middle East & Africa
- 10.5.1 Patient Population
- 10.5.2 Diagnosis Trends
- 10.5.3 Treatment Access

11. Key Countries Analysis

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 China
11.9 Japan
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Public Health and Healthcare System Impact

12.1 Healthcare Resource Utilization
- 12.1.1 Outpatient Visits
- 12.1.2 Emergency Department Utilization
- 12.1.3 Hospitalization Trends
12.2 Economic Burden Analysis
- 12.2.1 Direct Costs
- 12.2.2 Indirect Costs
- 12.2.3 Productivity Loss
12.3 Public Health Initiatives
- 12.3.1 Awareness Programs
- 12.3.2 Screening Initiatives
- 12.3.3 Access Improvement Programs

13. Future Outlook and Strategic Insights

13.1 Epidemiological Outlook
- 13.1.1 Population Growth Trends
- 13.1.2 Disease Burden Trends
- 13.1.3 Diagnosis Trends
13.2 Healthcare System Outlook
- 13.2.1 Access Expansion
- 13.2.2 Digital Health Adoption
- 13.2.3 Telemedicine Growth
13.3 Strategic Insights
- 13.3.1 High-Burden Populations
- 13.3.2 Underserved Regions
- 13.3.3 Future Healthcare Priorities

14. Methodology and Data Framework

14.1 Data Sources
- 14.1.1 Government Databases
- 14.1.2 Academic Publications
- 14.1.3 Disease Registries
- 14.1.4 International Health Organizations
14.2 Forecasting Framework
- 14.2.1 Population Modeling
- 14.2.2 Epidemiology Modeling
- 14.2.3 Validation Methodology
14.3 Quality Assurance
- 14.3.1 Data Verification
- 14.3.2 Cross-Source Validation
- 14.3.3 Limitation Assessment